| CPC A61K 9/5176 (2013.01) [A61K 9/0009 (2013.01); A61K 9/5123 (2013.01); A61K 31/7105 (2013.01); C12N 15/1136 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01)] | 3 Claims |
|
1. A preparation method for an ultrasound responsive lipid nanoparticle carrying genes and a cell membrane, wherein a surface of the ultrasound responsive lipid nanoparticle carrying the genes and the cell membrane is connected with small molecule nucleic acids based on a principle of charge adsorption, a component of the cell membrane is mixed in a surface lipid layer, perfluoropentane (PFP) is encapsulated inside the ultrasound responsive lipid nanoparticle carrying the genes and the cell membrane, liquid gas phase transition occurs under ultrasonic irradiation, and blasting occurs under continuous ultrasonic irradiation, a blasting energy generated forms reversible acoustic holes on a surface of the cell membrane, and a drug released after blasting is driven by a blasting driving force to directly enter an interior of a cell through the reversible acoustic holes, realizing an efficient release and transfection of nucleic acids in the cell; and the preparation method comprises:
(1) preparing a cationic ultrasonic phase change nanoparticle: mixing DSPC, DSPE, and DOTAP, and dissolving in dichloromethane, placing in a rotary evaporator to obtain a layer of uniform translucent film, adding ultrapure water, placing in an ultrasonic cleaner to completely elute the film to form a homogeneous and translucent suspension, transferring the suspension to a centrifuge tube, precooling on ice, adding an ultrasonic phase change material, changing the translucent suspension obtained into an opaque lotion after ultrasonic vibration to obtain an initial lotion with nanoparticles, centrifugating to remove excess impurities, to obtain the cationic ultrasonic phase change nanoparticle purified;
(2) preparing an ultrasonic phase change nanoparticle carrying a small molecule nucleic acid drug: mixing the cationic ultrasonic phase change nanoparticle prepared in the step (1) with the small molecule nucleic acids and incubating on ice, connecting the small molecule nucleic acids to a surface of lipid nanoparticles based on the principle of the charge adsorption, and forming charge reversal on the surface of the lipid nanoparticles to prepare the ultrasonic phase change nanoparticle carrying the small molecule nucleic acid drug;
(3) preparing a biomimetic ultrasound phase change nanoparticle carrying the small molecule nucleic acid drug: mixing the cell membrane with the ultrasonic phase change nanoparticle carrying the small molecule nucleic acid drug obtained in the step (2), adding a cell membrane component to a lipid shell component of the nanoparticle based on a fluidity of a lipid membrane by an acoustic vibration method, placing a mixture in an ice bath, adding the PFP to the mixture again, obtaining the biomimetic ultrasound phase change nanoparticle carrying the small molecule nucleic acid drug after ultrasonic vibration, and centrifugating to remove excess impurities, to obtain the biomimetic ultrasound phase change nanoparticle carrying the small molecule nucleic acid drug purified;
wherein in the step (1), a mass ratio of the DSPC, the DSPE, and the DOTAP is 10:4:2;
wherein in the step (1), the ultrasonic vibration uses an acoustic cell disruptor with a condition set to 90 W, a total time of 5 min, and a duty cycle of 50%; a condition of the rotary evaporator is set at 60° C. for 1 h; a purification is repeated by a low-temperature high-speed centrifuge, and a centrifugation condition is set at 12000 rpm at 4° C. for 15 min each time, a total of three times;
wherein in the step (1), the phase change material is liquid perfluoropentane referred to as the PFP, chemical formula C5F12, molecular weight 288.036 g/mol, perfluorinated analog of pentane, and the liquid gas phase transition occurs when ambient temperature reaches 29° C.;
wherein in the step (2), the cationic ultrasonic phase change nanoparticle is incubated with the small molecule nucleic acids at a charge ratio of 3:2;
wherein in the step (3), a centrifugation condition is set at 12000 rpm at 4° C. for 15 min every time, and three centrifugations are carried out.
|